organ/tissue transplant rejection
Immunology · 2019–2019
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tacrolimus Management of rejection in patients following organ or tissue transplantation. This submission concerned a new 3 mg once-daily prolonged-release strength. | Nov 2019 | Recommended | none received |
What the PBS pays
$42M in government benefit over 2024–25, across 183,298 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tacrolimus | $42.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.